Page 2043 - Williams Hematology ( PDFDrive )

2018 Part XII: Hemostasis and Thrombosis Chapter 117: Thrombocytopenia 2019

is typically severe. Among the 247 case reports with evidence for a def- 21. Savage RA: Pseudoleukocytosis due to EDTA-induced platelet clumping. Am J Clin
inite or probable causal relation of the drug to thrombocytopenia, 23 Pathol 81:317–322, 1984.
patients (9 percent) had major bleeding, including two patients who 22. Vicari A, Banfi G, Bonini PA: EDTA-dependent pseudothrombocytopaenia: A
12-month epidemiological study. Scand J Clin Lab Invest 48:537–542, 1988.
430
died of bleeding, and 68 patients (28 percent) had overt but minor 23. Sweeney JD, Holme S, Heaton WA, et al: Pseudothrombocytopenia in plateletpheresis
bleeding; 96 patients (39 percent) had only purpura or trivial bleed- donors. Transfusion 35:46–49, 1995.
430
ing, and the remainder had no bleeding. The time from beginning 24. Bartels PC, Schoorl M, Lombarts AJ: Screening for EDTA-dependent deviations in
platelet counts and abnormalities in platelet distribution histograms in pseudothrom-
the drug to the initial occurrence of thrombocytopenia varies from 1 bocytopenia. Scand J Clin Lab Invest 57:629–636, 1997.
day to 3 years, but the median time is 14 days. With rechallenge, acute 25. Bragagni G, Bianconcini G, Brogna R, Zoli G: [Pseudothrombocytopenia: Clinical
thrombocytopenia may occur within minutes but almost always within comment on 37 cases] [in Italian]. Minerva Med 92:13–17, 2001.
3 days. Patients may have other signs and symptoms of drug sensitiv- 26. Kurata Y, Hayashi S, Jouzaki K, et al: [Four cases of pseudothrombocytopenia due to
430
platelet cold agglutinins] [in Japanese]. Rinsho Ketsueki 47:781–786, 2006.
ity, such as nausea and vomiting, rash, fever, and abnormal liver func- 27. Reed BW, Go RS: Pseudothrombocytopenia associated with multiple myeloma. Mayo
450
tion tests. Laboratory data may demonstrate leukopenia, indicating Clin Proc 81:869, 2006.
450
that the drug-dependent antibodies target multiple cell types. Patients 28. Campbell V, Fosbury E, Bain BJ: Platelet phagocytosis as a cause of pseudothrombocy-
topenia. Am J Hematol 84:362, 2009.
who have systemic adverse reactions to drugs manifesting as TTP or 29. Onder O, Weinstein A, Hoyer LW: Pseudothrombocytopenia caused by platelet agglu-
HUS are described in Chap. 133. tinins that are reactive in blood anticoagulated with chelating agents. Blood 56:177–182,
1980.
30. Bizzaro N: EDTA-dependent pseudothrombocytopenia: A clinical and epidemiological
TREATMENT study of 112 cases, with 10-year follow-up. Am J Hematol 50:103–109, 1995.
31. Hoyt RH, Durie BG: Pseudothrombocytopenia induced by a monoclonal IgM kappa
Withdrawal of the offending drug is the most important therapeutic platelet agglutinin. Am J Hematol 31:50–52, 1989.
measure. Prednisone is commonly given because the distinction of 32. Bizzaro N, Goldschmeding R, von dem Borne AE. Platelet satellitism is Fc gamma RIII
(CD16) receptor-mediated. Am J Clin Pathol 103:740–744, 1995.
drug-induced thrombocytopenia from ITP is almost never clear ini- 33. Casonato A, Bertomoro A, Pontara E, et al: EDTA dependent pseudothrombocytope-
tially; however, glucocorticoids do not appear to speed recovery. In nia caused by antibodies against the cytoadhesive receptor of platelet gpIIB-IIIA. J Clin
450
patients with major bleeding, emergency treatment should be the same Pathol 47:625–630, 1994.
as for ITP: platelet transfusions, high doses of parenteral methylpred- 34. Nomura S, Nagata H, Oda K, et al: Effects of EDTA on the membrane glycoproteins
IIb-IIIa complex—Analysis using flow cytometry. Thromb Res 47:47–58, 1987.
nisolone, and possibly IVIG. 319 35. Schrezenmeier H, Muller H, Gunsilius E, et al: Anticoagulant-induced pseudothrom-
bocytopenia and pseudoleucocytosis. Thromb Haemost 73:506–513, 1995.
REFERENCES 36. Ryo R, Sugano W, Goto M, et al: Platelet release reaction during EDTA-induced platelet
agglutinations and inhibition of EDTA-induced platelet agglutination by anti-glycopro-
tein II b/III a complex monoclonal antibody. Thromb Res 74:265–272, 1994.
1. Morrell CN, Aggrey AA, Chapman LM, Modjesks KL: Emerging roles for platelets as 37. Cohen AM, Lewinski UH, Klein B, Djaldetti M: Satellitism of platelets to monocytes.
immune and inflammatory cells. Blood 123:2759–2767, 2014. Acta Haematol 64:61–64, 1980.
2. Kaushansky K: Historical review: Megakaryopoiesis and thrombopoiesis. Blood 111: 38. Djaldetti M, Fishman P: Satellitism of platelets to monocytes in a patient with hypogam-
981–986, 2008. maglobulinaemia. Scand J Haematol 21:305–308, 1978.
3. Brubaker DB, Marcus C, Holmes E: Intravascular and total body platelet equilibrium 39. Schell DA, Ganti AK, Levitt R, Potti A: Thrombocytopenia associated with c7E3 Fab
in healthy volunteers and in thrombocytopenic patients transfused with single donor (abciximab). Ann Hematol 81:76–79, 2002.
platelets. Am J Hematol 58:165–176, 1998. 40. Sane DC, Damaraju LV, Topol EJ, et al: Occurrence and clinical significance of pseu-
4. Hill-Zobel RL, McCandless B, Kang SA, et al: Organ distribution and fate of human dothrombocytopenia during abciximab therapy. J Am Coll Cardiol 36:75–83, 2000.
platelets: Studies of asplenic and splenomegalic patients. Am J Hematol 23:231–238, 41. Peters MN, Press CD, Moscona JC: Acute profound thrombocytopenia secondary to
1986. local abciximab infusion. Proc (Bayl Univ Med Cent) 25:346–348, 2012.
5. Heyns AD, Lotter MG, Badenhorst PN, et al: Kinetics, distribution and sites of destruc- 42. Berkowitz SD, Sane DC, Sigmon KN, et al: Occurrence and clinical significance of
tion of 111indium-labelled human platelets. Br J Haematol 44:269–280, 1980. thrombocytopenia in a population undergoing high-risk percutaneous coronary revas-
6. Heyns AD, Lotter MG, Badenhorst PN, et al: Kinetics and sites of destruction of cularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC)
111Indium-oxine-labeled platelets in idiopathic thrombocytopenic purpura: A quan- Study Group. J Am Coll Cardiol 32:311–319, 1998.
titative study. Am J Hematol 12:167–177, 1982. 43. Berkman N, Michaeli Y, Or R, Eldor A: EDTA-dependent pseudothrombocytopenia:
7. Leissinger CA: Platelet kinetics in immune thrombocytopenic purpura and human A clinical study of 18 patients and a review of the literature. Am J Hematol 36:195–201,
immunodeficiency virus thrombocytopenia. Curr Opin Hematol 8:299–305, 2001. 1991.
8. Hanson SR, Slichter SJ: Platelet kinetics in patients with bone marrow hypoplasia: 44. Mori M, Kudo H, Yoshitake S, et al: Transient EDTA-dependent pseudothrombocy-
Evidence for a fixed platelet requirement. Blood 66:1105–1109, 1985. topenia in a patient with sepsis. Intensive Care Med 26:218–220, 2000.
9. Pearse BM: Receptors compete for adaptors found in plasma membrane coated pits. 45. Bizzaro N, Fiorin F: Coexistence of erythrocyte agglutination and EDTA-dependent
EMBO J 7:3331–3336, 1988. platelet clumping in a patient with thymoma and plasmocytoma. Arch Pathol Lab Med
10. Kile BT: The role of apoptosis in megakaryocytes and platelets. Br J Haematol 165: 123:159–162, 1999.
217–226, 2015. 46. Matarazzo M, Conturso V, Di MM, et al: EDTA-dependent pseudothrombocytopenia
11. Bain BJ: Ethnic and sex differences in the total and differential white cell count and in a case of liver cirrhosis. Panminerva Med 42:155–157, 2000.
platelet count. J Clin Pathol 49:664–666, 1996. 47. Recommended methods for radioisotope platelet survival studies: By the panel on
12. Lozano M, Narvaez J, Faundez A: Platelet count and mean platelet volume in the Diagnostic Application of Radioisotopes in Hematology, International Committee for
Spanish population. Med Clin (Barc) 110:774–777, 1998. Standardization in Hematology. Blood 50:1137–1144, 1977.
13. Stasi R, Amadori S, Osborn J, et al: Long-term outcome of otherwise healthy individu- 48. Chiurazzi F, Villa MR, Rotoli B: Transplacental transmission of EDTA-dependent pseu-
als with incidentally discovered borderline thrombocytopenia. PLoS Med 3:e24, 2006. dothrombocytopenia. Haematologica 84:664, 1999.
14. Buckley MF, James JW, Brown DE: A novel approach to the assessment of variations in 49. Kortering JJ, Boersma B, Schoorl M, et al: Pseudothrombocytopenia in a neonate due to
human platelet count. Thromb Haemost 83:480–484, 2000. mother? Eur J Pediatr 172:987–989, 2013.
15. Buttarello M, Plebani M: Automated blood cell counts: State of the art. Am J Clin Pathol 50. Solanki DL, Blackburn BC: Spurious thrombocytopenia during pregnancy. Obstet
130:104–116, 2008. Gynecol 65:14S–17S, 1985.
16. Segal HC, Briggs C, Kunka S: Accuracy of platelet counting haematology analysers in 51. Diz-Kucukkaya R: Inherited platelet disorders including Glanzmann thrombasthenia
severe thrombocytopenia and potential impact on platelet transfusion. Br J Haematol and Bernard-Soulier syndrome. Hematology Am Soc Hematol Educ Program 2013:275,
128:520–525, 2005. 2013.
17. Salignac S, Latger-Cannard V, Schlegel N, Lecompte TP: Platelet. Methods Mol Biol 52. Bunimov N, Fuller N, Hayward CP: Genetic loci associated with platelet traits and
992:193–205, 2013. platelet disorders. Semin Thromb Hemost 39:291–305, 2013.
18. Yoneyama A, Nakahara K: [EDTA-dependent pseudothrombocytopenia—Differentia- 53. Watson SP, Lowe GC, Lordkipanidze M, Morgan NY: Genotyping and phenotyping of
tion from true thrombocytopenia] [in Japanese]. Nihon Rinsho 61:569–574, 2003. platelet function disorders. J Thromb Haemost 2013:351–363, 2013.
19. García Suárez J, Merino JL, Rodriguez M, et al: [Pseudothrombocytopenia: Incidence, 54. Diz-Kucukkaya R, López JA: Inherited disorders of platelets: Membrane glycoprotein
causes and methods of detection] [in Spanish]. Sangre (Barc) 36:197–200, 1991. disorders. Hematol Oncol Clin North Am 27:613–627, 2013.
20. Payne BA, Pierre RV: Pseudothrombocytopenia: A laboratory artifact with potentially 55. Gresele P: Diagnosis of inherited platelet function disorders: Guidance from the SSC of
serious consequences. Mayo Clin Proc 59:123–125, 1984. the ISTH. J Thromb Haemost 13:314–322, 2015.

Kaushansky_chapter 117_p1993-2024.indd 2018 9/21/15 2:33 PM